Table 4: Alternative therapeutic applications of allogeneic MSCs in liver cirrhosis patients.

Cell type Dose Route Sample size (n) Outcome Reference
UC-MSC Three median doses/0.5 × 106 per kg body weight Intravenous 43 Increased serum albumin, cholinesterase and platelet;
Decreased MELD score, prothrombin time, total bilirubin and ALT
[66]
UC-MSC Three median doses/0.5 × 106 per kg body weight Intravenous 7 Decreased serum alkaline phosphatase and γ-glutamyltransferase [25]
UC-MSC Three median doses/0.5 × 106 per kg body weight Intravenous 45 Improvement in liver function [25]
UC-MSC Single median dose/1.5 × 107 Percutaneous 51 Improved QULI [73]